Novoprotein Cloud Forum Series XVI – Empowering the Future: Opportunities and Challenges in Antibody Development for Multi-Pass Membrane Protein Targets

Multi-pass membrane proteins, including GPCRs (G protein-coupled receptors), ion channels, and transporters, play critical roles in the cell membrane and are closely associated with the onset and progression of many diseases. These proteins are structurally complex, typically containing multi-pass membrane domains (TMDs), which can lead to challenges such as instability and aggregation during expression and purification. Among approved small-molecule drugs, more than 50% target multi-pass membrane proteins. However, these drugs may lack specificity or interact with multiple signaling pathways, potentially resulting in safety concerns and side effects. Monoclonal antibodies (mAbs) targeting multi-pass membrane proteins offer an effective approach to achieve selective targeting. Nevertheless, these targets have historically been considered difficult or undruggable.

In response to the challenges of developing antibodies for structurally complex multi-pass membrane proteins, Novoprotein, in collaboration with the Chinese Antibody Society, is hosting an online forum. The forum will feature Dr. Guanyang Zhang from Novoprotein, who will introduce the NovoiSMART® technology platform and demonstrate how it supports the development of antibody therapeutics targeting multi-pass membrane proteins.

Click on the video below to access the official live stream replay.